MarketResearchReports.biz has recently announced the addition of a market study “ Systemic Mastocytosis - Pipeline Review, H2 2016”, is a comparative analysis of the global market.
Systemic Mastocytosis - Pipeline Review, H2 2016
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis Pipeline Review, H2 2016, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.
Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 1 respectively.Systemic Mastocytosis.
Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table Of Content
Table of Contents 2
List of Tables 5
List of Figures 5
Global Markets Direct Report Coverage 6
Systemic Mastocytosis Overview 7
Therapeutics Development 8
Pipeline Products for Systemic Mastocytosis - Overview 8
Systemic Mastocytosis - Therapeutics under Development by Companies 9
Systemic Mastocytosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Systemic Mastocytosis - Products under Development by Companies 13
Systemic Mastocytosis - Companies Involved in Therapeutics Development 14
AB Science SA 14
AbbVie Inc 15
Allakos Inc. 16
Arog Pharmaceuticals, Inc. 17
Blueprint Medicines Corporation 18
Bristol-Myers Squibb Company 19
Deciphera Pharmaceuticals, LLC 20
Novartis AG 21
Patara Pharma Inc 22
Stemline Therapeutics, Inc. 23
Systemic Mastocytosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AK-002 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BLU-285 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
crenolanib besylate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36